查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830070

肺炎鏈球菌疫苗市場（按疫苗類型、年齡層、分銷管道和最終用戶分類）—2025-2032 年全球預測

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年肺炎球菌疫苗市場將成長至 216.7 億美元，複合年成長率為 8.16%。

主要市場統計數據
基準年2024年 115.6億美元
預計2025年 124.9億美元
預測年份：2032年 216.7億美元
複合年成長率（%） 8.16%

構成當代肺炎鏈球菌疫苗接種優先事項和實施要務的最新臨床和政策進展的策略方向

肺炎鏈球菌疫苗領域正處於蓬勃發展的科學進步與不斷變化的公共衛生重點的交匯點。結合疫苗製劑的最新進展、成人和老年人群疫苗許可範圍的擴大以及對預防侵襲性肺炎球菌疾病的重新關注，正在再形成臨床指南和疫苗接種途徑。同時，監管機構不斷完善針對高風險族群的建議和季節性疫苗接種策略，促使醫療保健提供者和免疫接種計畫重新評估其疫苗接種政策和營運工作流程。

這些動態包括改進疫苗配方以擴大血清型覆蓋範圍，並透過最佳化供應鏈和醫療服務提供者教育，策略性地推動提高公平可及性。同時，製造商、公共衛生機構和臨床協會之間也加強了合作，以確保適應症、給藥方案和上市後監測的一致性。因此，從採購到臨床點的相關人員正在重新調整臨床方案和供應結構，以反映疫苗交付的科學進步和物流現實。

決策者必須清楚了解最新的臨床數據、政策更新和交付限制。整合這些要素有助於制定協調一致的策略，以設計疫苗接種計劃、制定處方決策並涵蓋高風險族群，確保臨床效益轉化為可衡量的公共衛生影響。

產品創新、監管調整和供應鏈現代化如何重新定義肺炎鏈球菌疫苗供應和臨床決策

在產品創新、監管調整和供應基礎日趨成熟的推動下，肺炎鏈球菌疫苗生態系統正經歷轉型變革。新型結合劑型能夠擴大血清型覆蓋範圍，正在改變臨床決策，並為前幾代疫苗未能充分覆蓋的成年人和老年人提供更廣泛的保護。這一演變強化了從依賴單一產品向多樣化選擇的轉變，臨床醫生和付款人必須根據臨床效益、操作可行性和成本效益進行評估。

同時，監管和諮詢委員會的指導方針正在根據新出現的證據進行調整，這為免疫接種計畫帶來了機會和營運挑戰。製造商正在採取以證據為導向的核准後生命週期策略，並與衛生部門合作，以確保擴大附加檔覆蓋範圍。同時，分銷網路和低溫運輸物流也日益複雜，整合了數位視覺化工具和區域夥伴關係關係，以減少浪費並擴大對服務匱乏地區的覆蓋範圍。

總體而言，這種轉變促使相關人員優先考慮敏捷採購、強化監測以及針對醫療保健提供者的有針對性的教育。透過使供應策略與臨床指導一致，衛生系統可以在能夠最大程度地提高公共衛生效益的領域促進疫苗接種，同時管理更廣泛的產品組合和不斷變化的疫苗接種計劃所帶來的物流複雜性。

評估貿易政策變化和關稅調整對疫苗供應鏈、採購彈性和交付連續性的下游營運影響

近年來，為調整關稅制度和貿易狀況而訂定的政策措施正在對支持疫苗生產和分銷的醫藥和醫療供應鏈產生實際影響。進口關稅的變化以及醫療投入審查通訊協定和實踐的變化可能會影響零件、低溫運輸設備和輔助用品的成本基礎，進而影響公共和私人免疫項目的籌資策略。當關稅波動導致關鍵投入品在岸採購成本增加時，製造商和經銷商通常會採取應對措施，例如最佳化採購、與供應商協商長期合約以及加快對本地製造能力的投資。

對於肺炎球菌疫苗而言，關稅調整的累積影響需要仔細審查涵蓋原始抗原採購、管瓶和注射器供應商以及溫控物流供應商的供應鏈。醫療保健機構和製造商越來越希望實現供應多元化和在岸化，以降低進口相關成本波動帶來的風險。同時，採購負責人也更加重視能夠鎖定供應承諾並明確海關相關延誤責任的合約條款。

因此，參與疫苗供應的組織正在重新評估其採購框架、低溫運輸容量預算假設以及應急計劃，以確保疫苗接種服務的連續性。這些調整凸顯了綜合供應鏈風險管理的重要性，該管理應將貿易政策動態以及臨床和營運方面的考慮納入考慮。

一個細分主導的框架，將疫苗類型區分、年齡優先、分銷管道和護理環境與營運和臨床決策聯繫起來。

細緻的細分視角清楚地闡明了產品屬性、患者人口統計、通路和護理環境如何影響需求模式和專案優先順序。疫苗類型分為結合疫苗和多醣體疫苗，結合疫苗中又包含特定劑型，例如PCV13、PCV15和PCV20。根據年齡層，針對成人、兒童和老年族群量身訂做臨床和計畫策略，同時考慮到易感性、併發症情況和建議給藥方案的差異。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將新型20價肺炎鏈球菌結合疫苗快速納入國家免疫規劃
  • 擴大公私合營，改善醫療資源匱乏地區的疫苗接種服務
  • 擴大對基於mRNA的肺炎球菌疫苗平台的投資，以加速開發
  • 非疫苗血清型的出現導致流行病學發生變化，推動了下一代製劑的發展
  • 監理機關加速核准加速新型肺炎鏈球菌疫苗的上市

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 肺炎鏈球菌疫苗市場（依疫苗類型）

  • 結合疫苗
    • PCV13
    • PCV15
    • PCV20
  • 多醣體疫苗

9. 肺炎鏈球菌疫苗市場（依年齡層）

  • 成人
  • 孩子
  • 老年人

第 10 章肺炎鏈球菌疫苗市場（按分銷管道）

  • 離線
  • 線上

第 11 章。肺炎鏈球菌疫苗市場（按最終用戶）

  • 門診治療中心
  • 診所
  • 醫院
  • 疫苗接種中心

12. 肺炎鏈球菌疫苗市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 肺炎鏈球菌疫苗市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按國家/地區分類的肺炎鏈球菌疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AstraZeneca PLC
    • Biological E. Limited
    • Biovac
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Incepta Pharmaceuticals Ltd.
    • Lonza AG
    • Merck & Co., Inc.
    • Panacea Biotec Limited
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Pvt. Ltd.
    • Vaxcyte Inc.
    • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market is projected to grow by USD 21.67 billion at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.56 billion
Estimated Year [2025] USD 12.49 billion
Forecast Year [2032] USD 21.67 billion
CAGR (%) 8.16%

A strategic orientation to recent clinical and policy advances that frame contemporary pneumococcal vaccination priorities and implementation imperatives

The pneumococcal vaccine landscape sits at the intersection of robust scientific advancement and evolving public health priorities. Recent developments in conjugate vaccine formulations, expanded licensure across adult and geriatric populations, and a renewed emphasis on preventing invasive pneumococcal disease have reshaped clinical guidelines and vaccination pathways. At the same time, regulatory bodies continue to refine recommendations for high-risk groups and seasonal immunization strategies, prompting healthcare providers and immunization programs to revisit coverage policies and operational workflows.

Across clinical and operational domains, two parallel dynamics are evident: the refinement of vaccine composition to broaden serotype coverage and a strategic push to improve equitable access through supply chain optimization and provider education. These dynamics are accompanied by intensified collaboration among manufacturers, public health agencies, and clinical societies to ensure alignment on indications, administration schedules, and post-marketing surveillance. As a result, stakeholders from procurement to point-of-care are recalibrating clinical protocols and supply arrangements to reflect both the scientific advances and the logistical realities of vaccine delivery.

For decision-makers, a clear understanding of recent clinical data, policy updates, and delivery constraints is essential. Integrating these elements supports coherent strategies for immunization program design, formulary decisions, and outreach to populations with elevated risk, thereby ensuring that clinical gains translate into measurable public health impact.

How product innovation, regulatory adaptation, and supply chain modernization are collectively redefining pneumococcal vaccine delivery and clinical decision-making

The pneumococcal vaccine ecosystem is undergoing transformative shifts driven by product innovation, regulatory recalibration, and the maturation of delivery infrastructures. Newer conjugate formulations expanding serotype coverage have altered clinical decision-making, facilitating broader protection for adults and older populations previously underserved by earlier vaccine generations. This evolution is reinforcing a transition from single-product reliance toward a diversified set of options that clinicians and payers must evaluate on the basis of clinical benefit, operational feasibility, and cost-effectiveness.

Meanwhile, regulatory pathways and advisory committee guidance are adapting to emerging evidence, creating both opportunities and operational challenges for immunization programs. Manufacturers are responding with lifecycle strategies that emphasize post-approval evidence and engagement with health authorities to secure label expansions. At the same time, distribution networks and cold chain logistics are becoming more sophisticated, integrating digital visibility tools and regional partnerships to reduce wastage and improve reach into under-immunized communities.

These shifts collectively encourage stakeholders to prioritize agile procurement, enhanced surveillance, and targeted provider education. By aligning supply strategies with clinical guidance, health systems can accelerate uptake where the public health benefit is greatest while managing the logistical complexity introduced by a broader product mix and evolving immunization schedules.

Assessing the downstream operational consequences of altered trade policies and tariff adjustments on vaccine supply chains, procurement resilience, and delivery continuity

Policy measures enacted in recent years to adjust tariff regimes and trade posture have had tangible implications for the pharmaceutical and medical supply chains that support vaccine production and distribution. Changes to import duties, review protocols for medical inputs, and enforcement practices can influence the cost base for components, cold chain equipment, and ancillary supplies, which in turn affects procurement strategies for public and private immunization programs. Where tariff shifts increase landed costs for critical inputs, manufacturers and distributors often respond by optimizing sourcing, negotiating longer-term supplier agreements, and accelerating investments in local manufacturing capabilities.

In the context of pneumococcal vaccines, the cumulative effect of tariff adjustments necessitates careful scrutiny of supply chains that span raw antigen procurement, vial and syringe suppliers, and temperature-controlled logistics providers. Health systems and manufacturers are increasingly focusing on supply diversification and onshoring initiatives to mitigate exposure to import-related cost volatility. Concurrently, procurement officers are placing greater emphasis on contractual terms that lock in supply commitments and clarify responsibility for customs-related delays.

As a result, organizations involved in vaccine delivery are revising procurement frameworks, budgeting assumptions for cold chain capacity, and contingency planning to ensure continuity of vaccination services. These adaptations underscore the importance of integrated supply chain risk management that accounts for trade policy dynamics alongside clinical and operational considerations.

A segmentation-driven framework linking vaccine type differentiation, age-specific priorities, distribution channels, and care settings to operational and clinical decision-making

A nuanced segmentation lens clarifies how product characteristics, patient demographics, distribution pathways, and care settings shape demand patterns and program priorities. Based on Vaccine Type, the landscape is evaluated across Conjugate Vaccine and Polysaccharide Vaccine, with conjugate options further differentiated by specific formulations including Pcv13, Pcv15, and Pcv20; these distinctions influence clinical recommendations, immunogenicity expectations, and cold chain handling requirements. Based on Age Group, clinical and program strategies are tailored for Adult, Children, and Geriatric cohorts given differences in susceptibility, comorbidity profiles, and recommended administration schedules.

Based on Distribution Channel, distribution dynamics vary between Offline and Online pathways, with traditional provider-administered channels remaining central to routine immunization while digital procurement and telehealth-enabled coordination are expanding access and convenience. Based on End User, program design and logistics are shaped by site-specific needs across Ambulatory Care Centers, Clinics, Hospitals, and Immunization Centers, each of which has distinct staffing models, cold storage capacity, and patient throughput patterns. Integrating these segmentation dimensions enables stakeholders to align product selection, education efforts, and logistics investments with the practical realities of each setting and population cohort.

This segmentation-driven approach facilitates targeted interventions, such as prioritizing high-valency conjugate formulations in settings serving older adults or optimizing online ordering workflows for smaller clinics, thereby improving alignment between clinical value and operational delivery.

Regional dynamics and tailored deployment strategies that reconcile diverse healthcare infrastructures, policy landscapes, and delivery priorities across major global regions

Regional dynamics continue to shape how pneumococcal vaccines are introduced, prioritized, and financed across diverse healthcare ecosystems. In the Americas, vaccination programs often balance strong public immunization infrastructure with varied payer arrangements and concentrated efforts to reach marginalized populations. Regional procurement strategies, national immunization schedules, and public health campaigns influence both uptake and program design, prompting collaboration between manufacturers and health authorities to address coverage gaps.

In Europe, Middle East & Africa, the environment is heterogeneous, with high-income health systems focusing on guideline alignment and adult immunization, while low- and middle-income settings prioritize pediatric access and cold chain expansion. Policy heterogeneity across this combined region underscores the need for adaptive distribution strategies and targeted support for regulatory harmonization and capacity building. In the Asia-Pacific region, rapid urbanization, expanding private healthcare delivery, and substantial investments in domestic manufacturing capacity are reshaping access models. Regional stakeholders are leveraging technology-enabled ordering, decentralized cold chain solutions, and partnerships to increase reach in both urban and rural settings.

Across these regions, manufacturers and public health entities must calibrate launch strategies, supply allocation, and educational outreach to reflect local regulatory processes, healthcare delivery models, and population health priorities. Such regional tailoring increases the effectiveness of immunization efforts and facilitates more efficient use of available resources.

Strategic manufacturer initiatives focusing on higher-valency formulations, manufacturing resilience, and evidence-generation to sustain clinical and commercial relevance

The competitive landscape in the pneumococcal vaccine field is characterized by a mix of legacy products and next-generation formulations, with companies focusing on lifecycle management, label expansions, and post-marketing evidence generation to sustain clinical relevance. Strategic priorities among leading manufacturers include advancing higher-valency conjugate options, strengthening regulatory dossiers for adult indications, and expanding manufacturing footprint to enhance supply reliability. Partnerships with contract manufacturers and investments in fill-and-finish capacity are common tactics to accelerate market readiness and reduce bottlenecks associated with sterile manufacturing.

In parallel, manufacturers are investing in real-world evidence programs and pharmacovigilance initiatives to support clinicians and payers in assessing comparative effectiveness and safety across populations. Engagement with advisory bodies and professional societies is central to shaping guideline updates and bolstering clinician confidence in new formulations. Commercial strategies increasingly emphasize value-based propositions that link clinical benefits with operational advantages such as reduced dosing complexity or improved stability at standard refrigeration temperatures.

For purchasers and health systems, understanding each company's manufacturing resilience, evidence-generation plans, and distribution partnerships is essential when assessing supply options. This insight helps inform procurement discussions, risk-sharing arrangements, and collaborative initiatives to expand access while maintaining consistent delivery performance.

Actionable measures for integrating clinical value with supply resilience, stakeholder engagement, and targeted access strategies to enhance vaccine program effectiveness

Industry leaders should prioritize a coherent set of actions that align clinical value, supply resilience, and equitable access. First, integrate product portfolio decisions with operational capabilities by ensuring that procurement strategies reflect differences in formulation requirements, cold chain needs, and administration schedules. This alignment reduces operational friction and supports consistent delivery across diverse care settings. Next, invest in collaborative supply agreements and capacity-building initiatives that reduce exposure to import-related volatility and strengthen regional fill-and-finish capabilities to support timely availability.

Additionally, elevate evidence synthesis and provider engagement efforts to accelerate appropriate uptake. Real-world safety and effectiveness data should be systematically collected and translated into concise clinical tools and decision aids for frontline clinicians. Strengthening partnerships with public health agencies and professional societies will facilitate guideline alignment and improve the clarity of risk-based recommendations. From a commercial perspective, consider structured contracting approaches that include performance clauses and supply continuity commitments, which can mitigate disruption risk and align incentives across stakeholders.

Finally, develop targeted outreach strategies for populations with lower uptake, leveraging digital platforms for appointment scheduling and vaccine reminders while reinforcing in-person access through community immunization centers. These combined steps will help organizations convert scientific advances into measurable improvements in population protection and program efficiency.

A mixed-methods research approach synthesizing clinical evidence, expert input, and operational review to produce actionable and validated insights for stakeholders

The research methodology underpinning this analysis combines systematic literature appraisal, targeted expert interviews, and supply chain review to ensure a robust and transparent evidence base. Peer-reviewed clinical studies, regulatory guidance documents, and publicly available safety surveillance reports formed the foundation for assessing clinical efficacy, indications, and post-authorization experience. Expert input was obtained from clinicians, vaccinologists, supply chain specialists, and health policy advisors to contextualize how evidence translates into operational and procurement decisions across care settings.

Operational insights were developed through examination of distribution channel dynamics, cold chain infrastructure reports, and procurement practice analyses, complemented by engagement with logistics providers and vaccination program managers to validate practical constraints and feasible solutions. Regulatory timelines and label expansions were reviewed to understand how product availability and indication alignment influence clinical practice. Where appropriate, triangulation of data sources and cross-validation with subject matter experts were used to resolve discrepancies and ensure analytical rigor.

This mixed-methods approach balances empirical evidence with practitioner expertise, producing actionable insights that reflect both scientific validity and the pragmatic realities of vaccine delivery and program implementation.

Integrated conclusions linking scientific advancement, regulatory evolution, and operational resilience to practical recommendations for advancing immunization outcomes

In summary, the pneumococcal vaccine environment is advancing along multiple dimensions: scientific innovation in conjugate formulations, evolving policy and guideline landscapes, and a growing emphasis on supply chain robustness. These forces are prompting stakeholders to rethink product selection, procurement strategies, and delivery models to ensure that clinical advances translate into expanded protection across age groups and care settings. Effective responses require integrated planning that spans regulatory engagement, manufacturing resilience, and targeted outreach to populations at elevated risk.

Moving from insight to action involves aligning evidence-generation with operational execution. Strengthened surveillance and real-world data programs, combined with strategic contracting and local capacity investments, can mitigate disruption risk and enhance access. At the clinical interface, continued education and clear guideline communication will be essential to harmonize practice patterns and optimize vaccine utilization across adult, pediatric, and geriatric populations. Ultimately, stakeholders that proactively coordinate clinical, commercial, and logistical strategies will be best positioned to convert recent innovations into sustained public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid integration of novel 20-valent pneumococcal conjugate vaccine in national immunization programs
  • 5.2. Expansion of public private partnerships to improve vaccine access in underserved regions
  • 5.3. Growing investment in mRNA based pneumococcal vaccine platforms for faster development
  • 5.4. Shifting epidemiology with emergence of non vaccine serotypes driving next generation formulations
  • 5.5. Regulatory accelerated approval pathways facilitating faster market entry for novel pneumococcal vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
    • 8.1.1. Pcv13
    • 8.1.2. Pcv15
    • 8.1.3. Pcv20
  • 8.2. Polysaccharide Vaccine

9. Pneumococcal Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Children
  • 9.3. Geriatric

10. Pneumococcal Vaccine Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Pneumococcal Vaccine Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Immunization Centers

12. Pneumococcal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pneumococcal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AstraZeneca PLC
    • 15.3.2. Biological E. Limited
    • 15.3.3. Biovac
    • 15.3.4. F. Hoffmann-La Roche AG
    • 15.3.5. GlaxoSmithKline plc
    • 15.3.6. Incepta Pharmaceuticals Ltd.
    • 15.3.7. Lonza AG
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Panacea Biotec Limited
    • 15.3.10. Pfizer, Inc.
    • 15.3.11. Sanofi SA
    • 15.3.12. Serum Institute of India Pvt. Ltd.
    • 15.3.13. Vaxcyte Inc.
    • 15.3.14. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV13, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV15, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PCV20, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 205. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 216. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 217. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 241. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 252. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 253. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 264. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 265. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 287. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 297. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 307. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 327. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2024 (USD MILLION)
  • TABLE 336. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2025-2032 (USD MILLION)
  • TABLE 337. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 338. FRANCE PNEUMOC